International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria
Résumé
BACKGROUND and AIMS: Good outcomes after liver transplantation (LT) have been reported after successfully downstaging to Milan criteria in more advanced hepatocellular carcinoma (HCC). We aimed to compare post-LT outcomes in patients receiving locoregional therapies (LRT) before LT according to Milan criteria and University of California San Francisco downstaging (UCSF-DS) protocol and ’all-comers’. METHODS: This multicentre cohort study included patients who received any LRT before LT from Europe and Latin America (2000-2018). We excluded patients with alpha-foetoprotein (AFP) above 1,000 ng/ml. Competing risk regression analysis for HCC recurrence was conducted, estimating subdistribution hazard ratios (SHRs) and corresponding 95% CIs. RESULTS: From 2,441 LT patients, 70.1% received LRT before LT (n = 1,711). Of these, 80.6% were within Milan, 12.0% within UCSF-DS, and 7.4% all-comers. Successful downstaging was achieved in 45.2% (CI 34.8-55.8) and 38.2% (CI 25.4-52.3) of the UCSF-DS group and all-comers, respectively. The risk of recurrence was higher for all-comers (SHR 6.01 [p <0.0001]) and not significantly higher for the UCSF-DS group (SHR 1.60 [p = 0.32]), compared with patients remaining within Milan. The all-comers presented more frequent features of aggressive HCC and higher tumour burden at explant. Among the UCSF-DS group, an AFP value of ≤20 ng/ml at listing was associated with lower recurrence (SHR 2.01 [p = 0.006]) and better survival. However, recurrence was still significantly high irrespective of AFP ≤20 ng/ml in all-comers. CONCLUSIONS: Patients within the UCSF-DS protocol at listing have similar post-transplant outcomes compared with those within Milan when successfully downstaged. Meanwhile, all-comers have a higher recurrence and inferior survival irrespective of response to LRT. Additionally, in the UCSF-DS group, an ALP of ≤20 ng/ml might be a novel tool to optimise selection of candidates for LT. CLINICAL TRIAL NUMBER: This study was registered as part of an open public registry (NCT03775863). LAY SUMMARY: Patients with more extended HCC (within the UCSF-DS protocol) successfully downstaged to the conventional Milan criteria do not have a higher recurrence rate after LT compared with the group remaining in the Milan criteria from listing to transplantation. Moreover, in the UCSF-DS patient group, an ALP value equal to or below 20 ng/ml at listing might be a novel tool to further optimise selection of candidates for LT.
Mots clés
AC
All-comers
AFP
Alpha-foetoprotein
DS
Downstaging
EASL
European Association for the Study of the Liver
HCC
Hepatocellular carcinoma
HR
Hazard ratio
ITT
Intention to treat
LR
Liver resection
LRT
Locoregional therapies
LT
Liver transplantation
MC
Milan criteria
MVI
Microvascular invasion
PEI
Percutaneous ethanol ablation
RFA
Radiofrequency ablation
SHR
Subdistribution hazard ratio
TACE
Transarterial chemoembolisation
UCSF downstaging protocol
UCSF-DS
University of California San Francisco downstaging
UNOS
United Network for Organ Sharing
WL
Waiting list
Fichier principal
Degroote-2021-International study on the outcome of locoregional therapy.pdf (680.03 Ko)
Télécharger le fichier
Degroote_ScienceDirect_files_14Oct2021_14-46-37.684.zip (4.33 Mo)
Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte